Watching safety of Talzenna in real-world patients
Part of Cancer, Skin clinical trials.
This study follows people in Korea who are starting Talzenna® as decided by their doctor. It mainly collects safety and real-world use information, helping Pfizer monitor how the medicine works outside of tightly controlled trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your doctor has decided to start you on Talzenna® for your care
- You (or a legal representative) can sign and date a consent form after being told about the study
- You do not have a known allergy to Talzenna® or any medicine ingredients
- You are not breastfeeding
- You agree to let Pfizer and partner companies use your study information
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how people feel (patient-reported outcomes) and their real-world health data while they receive trastuzumab deruxtecan for advanced HER2-positive, HER2-low, or HER2-ultralow breast cancer. It helps researchers understand what outcomes happen outside of tightly controlled clinical trials.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
This study looks at real-world safety data for patients in South Korea who are taking Capivasertib as prescribed by their doctor according to the approved label. It helps ensure the drug continues to be safe and effective for people who need it.
This study watches how patients in Korea do while taking Tukysa for the first time. It helps doctors learn more about how the medicine works in real life.
This trial tests a new oral medication called Zn-Telomir in patients with triple-negative breast cancer that has spread or cannot be surgically removed. The drug may help slow or shrink tumors in people whose cancer has grown despite prior treatments.
This trial studies talquetamab, a medicine given to treat multiple myeloma that has come back or did not respond to prior treatment. It may help shrink tumors and improve disease control, depending on how your myeloma measures and your health status.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.